Publications by authors named "Tomoko Yasuhiro"

Claim this Profile
T
Triple combination therapy comprising osimertinib, an AXL inhibitor, and an FGFR inhibitor improves the efficacy of EGFR-mutated non-small cell lung cancer.
Ryota Nakamura, Tadaaki Yamada, Shinsaku Tokuda, Kenji Morimoto, Yuki Katayama, Tomoko Yasuhiro

Cancer Lett· August 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Investigation of the anti-tumor mechanism of tirabrutinib, a highly selective Bruton's tyrosine kinase inhibitor, by phosphoproteomics and transcriptomics.
Ryohei Kozaki, Tomoko Yasuhiro, Hikaru Kato, Jun Murai, Shingo Hotta

PLoS One· March 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
AXL/MERTK inhibitor ONO-7475 potently synergizes with venetoclax and overcomes venetoclax resistance to kill -ITD acute myeloid leukemia.
Sean M Post, Huaxian Ma, Prerna Malaney, Xiaorui Zhang, Marisa J L Aitken, Tomoko Yasuhiro

Haematologica· June 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Anti-tumor efficacy study of the Bruton's tyrosine kinase (BTK) inhibitor, ONO/GS-4059, in combination with the glycoengineered type II anti-CD20 monoclonal antibody obinutuzumab (GA101) demonstrates superior in vivo efficacy compared to ONO/GS-4059 in combination with rituximab.
Tomoko Yasuhiro, Wako Sawada, Christian Klein, Ryohei Kozaki, Shingo Hotta

Leuk Lymphoma· March 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis